drugset / Trial / NCT06313996
A Study to Evaluate the Efficacy and Safety of Liso-cel Compared to Standard of Care in Adults With Relapsed or Refractory Follicular Lymphoma
Phase 3
Withdrawn
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Celgene Corporation · collab
RandomizedParallel-groupSingle-blindTreatment
Summary
The purpose of this study is to evaluate the efficacy and safety of Liso-cel compared to standard of care in adults with Relapsed or Refractory Follicular Lymphoma.
Timeline
- Start
- 2024-03-29
- Primary completion
- 2031-10-16
- Completion
- 2031-10-16
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Bendamustine | Small molecule | — | — |
| Comparator | Cyclophosphamide | Other / unclassified | — | — |
| Comparator | Doxorubicin | Other / unclassified | — | — |
| Comparator | Lenalidomide | Other / unclassified | — | — |
| Subject | Lisocabtagene Maraleucel | Cell therapy | — | — |
| Comparator | Prednisone | Other / unclassified | — | — |
| Comparator | Rituximab | Monoclonal antibody | — | — |
| Comparator | Vincristine | Small molecule | — | — |
| Background | Fludarabine | Small molecule | — | — |